Abstract: A blood conduit with stent has a flexible conduit body and an expandable stent structure. The conduit body has a first opening end through which only an inflow of a blood enters and a second opening end through which only an outflow of the blood leaves. The stent structure includes a plurality of threads adhered to the conduit body and expands in directions intersecting an axial direction of the conduit body. A boundary of one of the threads of the stent structure closest to the second opening end is away from the second opening end with a predetermined distance, thereby preventing blood back flow into the false lumen via a new tear.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: A blood conduit with stent has a flexible conduit body and an expandable stent structure. The conduit body has a first opening end through which only an inflow of a blood enters and a second opening end through which only an outflow of the blood leaves. The stent structure includes a plurality of threads adhered to the conduit body and expands in directions intersecting an axial direction of the conduit body. A boundary of one of the threads of the stent structure closest to the second opening end is away from the second opening end with a predetermined distance, thereby preventing blood back flow into the false lumen via a new tear.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Abstract: A union for connection of artificial vessel to human vessel is provided. The union is made of a biocompatible material, such as titanium, for fixedly positioning in an open end of an artificial vessel before a cut human vessel is put around the same open end of the artificial vessel and fixedly connected thereto with a binding string wound around the human vessel against a predetermined location on the union. The union allows the artificial vessel to be quickly connected to the cut human vessel to reduce bleeding and time needed to complete a surgical operation. And, the positioning of the union in the artificial vessel also reduces the difference between an outer diameter of the human vessel and an inner diameter of the artificial vessel at the joint of the two vessels.

Abstract: A blood pumping device includes a receptacle for receiving blood and having a non-valved inlet and outlet openings coupled to an aorta and the femoral artery. The receptacle includes a surface having a peripheral portion coupled to a peripheral portion of a diaphragm, and having a port coupled to a pump. The pump may shrink the diaphragm to draw the blood into the receptacle and may expand the diaphragm to pump the blood in the chamber of the receptacle out of the inlet opening and the outlet opening of the receptacle and into the aorta and the femoral artery of the patient.

Abstract: A porous polyurethane tube suitable for use as a vascular graft prosthesis is prepared by placing solvent type polyurethane resin coated mandrel in a static coagulant consisting of water, ethanol and optionally aprotic solvent within 30 seconds immediately after the coating step, separating the tube by placing the mandrel in a swelling agent containing at least 90 percent by weight of ethanol and rinsing with a solution containing at least 80 percent by weight ethanol.